Compare 10X Genomics Inc (TXG) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Wipro Limited — how do they compare? 10X Genomics Inc trades at $84.15 (market cap $10.07B), while Wipro Limited trades at $1.71 (market cap $16.22B). The key difference: Wipro Limited is the larger of the two by market cap, and Wipro Limited pays a 5.19% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 92 Days and Wipro Limited for 41 Days on average.
| TXG | WIT | |
|---|---|---|
Market Cap | $10.07B | $16.22B |
Volume | 5,657,286 | 9,028,667 |
Sector | Health | Technology |
52-Week High | $97.74 | $3.06 |
52-Week Low | $11.48 | $1.61 |
Typical Hold Time | 92 Days | 41 Days |
Enterprise Value | $9.59B | $14.33B |
Dividend Yield | — | 5.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
WIT trades at $1.67, down 0.6% on the day, with a bearish technical signal from moving averages and a neutral stance from oscillators. The company reported revenue of $890.88 billion in 2025 with a net income margin of 13.92%, though recent quarters have seen earnings misses against expectations. Recent news highlights Wipro's AI initiatives boosting productivity and new cybersecurity partnerships.
The outlook is mixed; valuation ratios like a P/E of 12.78 appear reasonable, but analyst consensus is cautious with only 19% buy ratings. Key risks include competitive pressures and macroeconomic uncertainty affecting tech spending. Upside hinges on execution of AI strategies and reversing earnings misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
